Gowling WLG’s Life Sciences team, led by partner Patrick Duxbury and including associate Kathryn Charles, have advised client Crescendo Biologics on its collaboration with Takeda Pharmaceutical Company Limited to discover, develop and commercialise Humabody-based therapeutics aimed at cancer indications with a high unmet medical need.
Crescendo, which develops Humabody-based therapeutics, will use its patented transgenic platform and protein engineering specialism to discover and develop Humabody candidates (Humabody drug conjugates and immune-oncology modulators) against oncology targets nominated by Takeda.
